Low-density lipoprotein (LDL) is sensitive to oxidative injury, and oxidized LDL (oxLDL) represents the major modified form of native LDL. There is evidence of the role of oxLDL in the initiation of atherosclerosis and its progression, plaque rupture, and thus cardiovascular diseases.1 This study evaluated the association between oxLDL levels and stroke recurrence in 3,019 patients with minor stroke or TIA included in the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events (CHANCE) trial.2 Overall, the study was properly conducted, although the oxLDL-4E6 antibody, which has potential cross-reactivity with native LDL and cannot detect oxLDL with <60 lysine modifications, was used for the determination of circulating oxLDL levels.

Source link